-+ 0.00%
-+ 0.00%
-+ 0.00%

Regenxbio reports 3-year durability data for sura-vec in Phase II ALTITUDE diabetic retinopathy trial

PUBT·09/24/2026 23:18:53
Listen to the news
Regenxbio reports 3-year durability data for sura-vec in Phase II ALTITUDE diabetic retinopathy trial
  • Regenxbio disclosed three-year follow-up results from its Phase II ALTITUDE study of sura-vec in non-proliferative diabetic retinopathy.
  • The data were already presented at the Retina Society Annual Scientific Meeting in Los Angeles.
  • Most patients at the selected dose showed sustained disease improvement without needing additional diabetic retinopathy treatment.
  • No vision-threatening events were reported in responders; the safety profile stayed consistent over long-term follow-up.
  • The same dose is being tested in the Phase IIb/III NAAVIGATE trial, supporting a potential one-time, in-office approach.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609241917PR_NEWS_USPR_____PH56710) on September 24, 2026, and is solely responsible for the information contained therein.